CAROL OW: Open Payments
NPI 1609307016 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,749 in 72 payments from 11 companies in 2025. Trend: 2023 $349 · 2024 $2,192 · 2025 $1,749
Food & beverage: $1,650Education: $99
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $393 |
| Ardelyx, Inc. | 11 | $284 |
| QOL Medical, LLC | 9 | $241 |
| Madrigal Pharmaceuticals | 9 | $224 |
| Janssen Biotech, Inc. | 6 | $214 |
| Novo Nordisk Inc | 4 | $121 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $92 |
| Phathom Pharmaceuticals, Inc. | 4 | $84 |
| Celltrion USA Inc. | 2 | $36 |
| Braintree Laboratories, Inc. | 2 | $35 |
Products named: IBSRELA, Sucraid, REZDIFFRA, TREMFYA, RINVOQ, Wegovy, XIFAXAN, LINZESS.
Industry payments across CA — which companies pay providers there.
